CBF Cobra Bio-Man.

    RNS Number : 2131W
  Cobra Bio-Manufacturing PLC
  09 June 2008
   

 For Immediate Release  9th June 2008
    

    Cobra Biomanufacturing Plc
    Cobrabio Announces Manufacturing Agreement with ViroMed for VM206RY

    Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has
signed an agreement with ViroMed Co., Ltd. in Korea to produce VM206RY, a plasmid DNA treatment for tumours expressing Her2/neu (breast,
ovarian, pancreatic, and stomach cancers).  Under the agreement, Cobrabio will produce ViroMed's Master Cell Bank and GMP-grade VM206RY for
clinical trials which will be held in Korea and in the United States.

    Simon Saxby, Chief Executive of Cobra Biomanufacturing said:
    "We are delighted to continue our partnership with ViroMed. In a recent ViroMed project, Cobrabio demonstrated that our commitment to
world class science, cGMP quality compliance and customer service provides the additional resources that leading biotech companies such as
ViroMed require to drive their research and development programmes forward.  ViroMed is Cobra's first client in Asia and we are pleased to
extend our services to this fast-growing life sciences market."

    Dr. Sunyoung Kim, CEO of ViroMed Co., Ltd. said:
    "We are pleased to extend our relationship with Cobrabio to our VM206RY plasmid project. ViroMed is a rapidly expanding company with a
growing pipeline of products in development and it is vital that we work with partners who can match our scientific expertise as well as our
commitment to quality."

    - ENDS -
    For further information, please contact:   

 Cobra Biomanufacturing Plc            Tel: +44 (0) 1782 714 181
 Simon Saxby, Chief Executive Officer

 Buchanan Communications               Tel: +44 (0) 207 466 5000
 Tim Anderson/Rebecca Skye Dietrich 

 College Hill Life Sciences            Tel: +44 (0) 20 7457 2020
 Gemma Price

 Seymour Pierce (NOMAD & Broker)       Tel: +44 (0) 207 107 8000
 Stuart Lane


    Notes to Editors:

    About Cobra Biomanufacturing Plc:
    Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992,
Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and
recombinant protein products. 

    Cobrabio has developed a range of unique, patented technologies, which underpin a successful revenue generating contract manufacturing
business.
    www.cobrabio.com 
This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCFKAKNPBKDCAK

Cobra Bio-manufacturing (LSE:CBF)
Historical Stock Chart
From Jun 2024 to Jul 2024

Cobra Bio-manufacturing (LSE:CBF)
Historical Stock Chart
From Jul 2023 to Jul 2024